UCB S.A. UNSP.ADR 1/2 revenue breakdown overview

UCB S.A. UNSP.ADR 1/2 revenue for the last year amounted to 5.16 B EUR, the most of which — 4.77 B EUR — came from its highest performing source at the moment, Biopharmaceuticals, the year earlier bringing 5.05 B EUR. The greatest contribution to the revenue figure was made by United States — last year it brought UCB S.A. UNSP.ADR 1/2 2.40 B EUR, and the year before that — 2.85 B EUR.